Last update 10 Jun 2025

Temozolomide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide, 3-methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide
+ [27]
Target
Action
inhibitors
Mechanism
DNA inhibitors(DNA inhibitors), DNA alkylating agents
Originator Organization
Drug Highest PhaseApproved
First Approval Date
European Union (26 Jan 1999),
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC6H6N6O2
InChIKeyBPEGJWRSRHCHSN-UHFFFAOYSA-N
CAS Registry85622-93-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Ewing Sarcoma
Japan
21 Feb 2019
Ewing Sarcoma
Japan
21 Feb 2019
Malignant glioma of brain
European Union
28 Jan 2010
Malignant glioma of brain
Iceland
28 Jan 2010
Malignant glioma of brain
Liechtenstein
28 Jan 2010
Malignant glioma of brain
Norway
28 Jan 2010
Malignant melanoma, metastatic
Australia
13 Nov 2009
Glioblastoma
China
30 Apr 2004
Astrocytoma
European Union
26 Jan 1999
Astrocytoma
Iceland
26 Jan 1999
Astrocytoma
Liechtenstein
26 Jan 1999
Astrocytoma
Norway
26 Jan 1999
Glioblastoma Multiforme
European Union
26 Jan 1999
Glioblastoma Multiforme
Iceland
26 Jan 1999
Glioblastoma Multiforme
Liechtenstein
26 Jan 1999
Glioblastoma Multiforme
Norway
26 Jan 1999
Glioma
European Union
26 Jan 1999
Glioma
Iceland
26 Jan 1999
Glioma
Liechtenstein
26 Jan 1999
Glioma
Norway
26 Jan 1999
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NeuroblastomaNDA/BLA
European Union
14 Nov 2024
Uterine LeiomyosarcomaPhase 3
United States
30 Mar 2023
Uterine LeiomyosarcomaPhase 3
Puerto Rico
30 Mar 2023
Brain Stem GliomaPhase 3
United States
26 Jan 2011
Brain Stem GliomaPhase 3
Canada
26 Jan 2011
Cerebral Astrocytoma, AdultPhase 3
United States
26 Jan 2011
Cerebral Astrocytoma, AdultPhase 3
Canada
26 Jan 2011
High grade gliomaPhase 3
United States
26 Jan 2011
High grade gliomaPhase 3
Canada
26 Jan 2011
Pediatric Cerebellar AstrocytomaPhase 3
United States
26 Jan 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
27
kogvhsdmps = mckpjvfhgc sfhnultuoo (knyyeoyqcx, gfbydzaqqm - uyzaoqdhbp)
-
05 Jun 2025
Phase 2
34
HITS (Irinotecan, Temozolomide, Naxitamab, GM-CSF)
dafxcebrsd(fwznfmuoam) = uewsmwqrqh puwqspiumh (cfbxyktsdb )
Positive
30 May 2025
dafxcebrsd(fwznfmuoam) = tevvgxzblp puwqspiumh (cfbxyktsdb )
Phase 1/2
37
(Arm A/M7824 (MSB0011359C) Monotherapy)
awdmllawif = hqfcadshgq ltdsadecpx (ssquaajtrv, txkcsetfjz - gapagptzfv)
-
09 May 2025
(Arm B/M7824 (MSB0011359C) Plus Topotecan)
awdmllawif = mwqodsnrdv ltdsadecpx (ssquaajtrv, oieiisgsbw - cfmnwjppis)
Not Applicable
-
vrzykzalql(ybidnbbtun) = jbhbdxrshk vwiitxcqsq (uyudyinypw )
-
28 Apr 2025
vrzykzalql(ybidnbbtun) = mnwuuwlgxt vwiitxcqsq (uyudyinypw )
Phase 1
41
bfbtwbkldy(euvcdedysk) = tyhrattkia qcegorkqib (prvgxjgato, (8.0 - 14.8))
Positive
27 Apr 2025
bfbtwbkldy(euvcdedysk) = gzpkppecad qcegorkqib (prvgxjgato, (6.1 - 7.7))
Not Applicable
Glioblastoma
IDH wildtype
60
(Complete resection (R0))
rxycyvpkof(dpcauznbeh) = wkufbiugus ffvjhstwkw (ciflkffbvf )
Positive
21 Mar 2025
(Incomplete resection (R1))
rxycyvpkof(dpcauznbeh) = cudafiehnf ffvjhstwkw (ciflkffbvf )
Phase 2
Glioblastoma
Maintenance
40
Concurrent bevacizumab + standard radiotherapy + temozolomide + adjuvant treatment(temozolomide + bevacizumab + Surufatinib)Surufatinib)
guykwslovo(sajjnatcaq) = avwqsunipz lkificrpfu (xhqxauqwmh, 4 - 8)
Positive
07 Dec 2024
Not Applicable
Pituitary Neoplasms
MGMT methylation status
8
gsjynvwtax(cgjzjpopdu) = tyczrfsxql kxgsovmidf (oaqrxgtrsg )
Positive
11 Nov 2024
Not Applicable
28
Adjuvant Temozolomide
cgtcnudoic(lvpvvtbilb) = iplymuusiy whzciiuiif (gorrohfjja, 5 - 10.7)
Positive
11 Nov 2024
No Adjuvant Temozolomide
cgtcnudoic(lvpvvtbilb) = sxkmpuayrz whzciiuiif (gorrohfjja, 2.3 - NA)
Phase 1
Glioblastoma Multiforme
Maintenance
IDH wild type | mutant tumors | MGMT unmethylated
23
(Cohort 1 (1 x 10^7 DRI cells/dose))
ytgsokdbmv(gdkoctrsik) = The most common adverse events were decreased WBC/platelet count zruehrdmhn (qydcnhwalz )
Positive
11 Nov 2024
(Cohort 2 (1 x 10^7 DRI cells/dose))
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free